<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04047719</url>
  </required_header>
  <id_info>
    <org_study_id>KDC-010</org_study_id>
    <nct_id>NCT04047719</nct_id>
  </id_info>
  <brief_title>Pneumonia in the ImmunoCompromised - Use of the Karius Test for the Detection of Undiagnosed Pathogens</brief_title>
  <acronym>PICKUP</acronym>
  <official_title>Pneumonia in the ImmunoCompromised - Use of the Karius Test for the Detection of Undiagnosed Pathogens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karius, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke Clinical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karius, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Given the need for a more sensitive pathogen detection test in patients with
      immunocompromised pneumonia, this study will evaluate the performance of the Karius Test, a
      novel NGS blood test for the diagnosis of infectious diseases. We will compare the
      performance of the Karius Test to the results of microbiologic tests obtained as part of
      usual care for immunocompromised patients undergoing evaluation for suspected pneumonia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pneumonia is a major cause of morbidity and mortality in highly immunocompromised individuals
      such as patients with hematologic malignancies or undergoing hematopoietic stem-cell
      transplantation. These patients can be infected by a broad range of potential pathogens,
      including viral, bacterial, and fungal etiologies and sometimes with multiple pathogens
      simultaneously. Diagnostic testing often fails to identify a microbial etiology for lower
      respiratory illness even with bronchoalveolar lavage (BAL). In fact, culture methods, PCR,
      and antigen testing on BAL samples yields a positive result only 30-67% of the time.
      Additionally, Idiopathic Pulmonary Syndrome (IPS), a non-infectious pulmonary complication of
      transplant, can have many overlapping symptoms with infectious pneumonia. Treatment for IPS
      is administration of steroids which can exacerbate infections. Given these reasons, there is
      a need for better diagnostics to aid in the management of immunocompromised patients with
      pneumonia.

      Karius has developed a microbial cell-free plasma next-generation sequencing test for
      pathogen detection capable of detecting &gt;1,000 organisms including DNA viruses, bacteria,
      yeasts, molds, and other eukaryotic pathogens. The test is performed in a
      CLIA-certified/CAP-accredited laboratory with results typically provided within one day from
      sample receipt. Given the need for a more sensitive diagnostic test for pneumonia in this
      population, we are evaluating the performance of the Karius Test for pathogen detection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Additive clinical diagnostic value</measure>
    <time_frame>7 days</time_frame>
    <description>Percent of patients with ≥1 pathogen identified by the Karius Test at enrollment adjudicated as a definite or probable cause of the subject's index pneumonia event with no pathogen identified as a definite or probable cause of the subject's index pneumonia event from an adjudicated composite of all microbiologic test results performed per standard of care iwth results available within 7 days of study enrollment</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">195</enrollment>
  <condition>Pneumonia, Bacterial</condition>
  <condition>Pneumonia, Viral</condition>
  <condition>Pneumonia Fungal</condition>
  <condition>Pneumonia Cavitary</condition>
  <condition>Immunocompromised Host</condition>
  <arm_group>
    <arm_group_label>Intent-to-Diagnose Population</arm_group_label>
    <description>All subjects enrolled in the study that have at least one Karius Test with a valid result</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Karius Test</intervention_name>
    <description>Karius Test for detection of microbial cell free DNA (mcfDNA) in plasma</description>
    <arm_group_label>Intent-to-Diagnose Population</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Immunocompromised patients with hematologic malignancies ≥ 18 years of age who are being
        evaluated for infectious pneumonia
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients are eligible for the study if they meet all of the following criteria:

          1. ≥ 18 years of age

          2. Have one of the following hematologic malignancies: Acute Lymphoblastic Leukemia
             (ALL), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Lymphoma (all
             types), or Multiple Myeloma (MM)

          3. Are immunocompromised defined as having at least one of the following:

               1. Received chemotherapy within the past 30 days

               2. Undergone hematopoietic stem cell transplantation (HSCT) within the past 1 year

               3. Active graft vs host disease (GVHD) requiring immunosuppressive pharmacologic
                  treatment

          4. Are admitted to the hospital with suspected infectious pneumonia warranting diagnostic
             evaluation and treatment

          5. Have a planned diagnostic bronchoscopy or have undergone a diagnostic bronchoscopy for
             the evaluation of the microbiologic etiology of pneumonia within the 24 hours prior to
             enrollment

        Exclusion Criteria:

        Patients are not eligible for the study if they meet any of the following criteria:

          1. Patient or patient's legally authorized representative does not provide consent for
             the study

          2. Patient is moribund and, in the opinion of the treating physician, is not expected to
             survive &gt;24 hours beyond the time of potential study enrollment visit

          3. Microbiologic etiology of index pneumonia event has already been identified per usual
             care testing

          4. Patient was previously enrolled in this study

          5. Patient has any condition that, in the opinion of the treating physician, will prevent
             the patient from completing the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Bergin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sudeb Dalai, MD, PhD</last_name>
    <phone>650-409-5007</phone>
    <phone_ext>167</phone_ext>
    <email>sudeb.dalai@kariusdx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stacy Meluskey, BS</last_name>
    <phone>510-258-9079</phone>
    <email>stacy.meluskey@kariusdx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Bergin</last_name>
      <phone>919-613-6394</phone>
      <email>stephen.bergin@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Matthew Kummerer</last_name>
      <phone>919-668-3135</phone>
      <email>Matthew.Kummerer@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Stephen Bergin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghady Haidar, MD</last_name>
      <phone>412-648-6212</phone>
      <email>haidar@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Joshua Kohl</last_name>
      <phone>412-648-6556</phone>
      <email>kohlj@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Haidar Ghady, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Hill, MD</last_name>
      <phone>206-667-6504</phone>
      <email>jahill13@fredhutch.org</email>
    </contact>
    <contact_backup>
      <last_name>Jacob Keane-Candib</last_name>
      <phone>206-667-6504</phone>
      <email>jkeaneca@fredhutch.org</email>
    </contact_backup>
    <investigator>
      <last_name>Joshua Hill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Norton ME, Baer RJ, Wapner RJ, Kuppermann M, Jelliffe-Pawlowski LL, Currier RJ. Cell-free DNA vs sequential screening for the detection of fetal chromosomal abnormalities. Am J Obstet Gynecol. 2016 Jun;214(6):727.e1-6. doi: 10.1016/j.ajog.2015.12.018. Epub 2015 Dec 18.</citation>
    <PMID>26709085</PMID>
  </reference>
  <reference>
    <citation>Alix-Panabières C, Pantel K. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. Cancer Discov. 2016 May;6(5):479-91. doi: 10.1158/2159-8290.CD-15-1483. Epub 2016 Mar 11. Review.</citation>
    <PMID>26969689</PMID>
  </reference>
  <reference>
    <citation>Evans SE, Ost DE. Pneumonia in the neutropenic cancer patient. Curr Opin Pulm Med. 2015 May;21(3):260-71. doi: 10.1097/MCP.0000000000000156. Review.</citation>
    <PMID>25784246</PMID>
  </reference>
  <reference>
    <citation>Schuster MG, Cleveland AA, Dubberke ER, Kauffman CA, Avery RK, Husain S, Paterson DL, Silveira FP, Chiller TM, Benedict K, Murphy K, Pappas PG. Infections in Hematopoietic Cell Transplant Recipients: Results From the Organ Transplant Infection Project, a Multicenter, Prospective, Cohort Study. Open Forum Infect Dis. 2017 Mar 22;4(2):ofx050. doi: 10.1093/ofid/ofx050. eCollection 2017 Spring.</citation>
    <PMID>28491889</PMID>
  </reference>
  <reference>
    <citation>Chen CS, Boeckh M, Seidel K, Clark JG, Kansu E, Madtes DK, Wagner JL, Witherspoon RP, Anasetti C, Appelbaum FR, Bensinger WI, Deeg HJ, Martin PJ, Sanders JE, Storb R, Storek J, Wade J, Siadak M, Flowers ME, Sullivan KM. Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003 Sep;32(5):515-22.</citation>
    <PMID>12942099</PMID>
  </reference>
  <reference>
    <citation>Harris B, Geyer AI. Diagnostic Evaluation of Pulmonary Abnormalities in Patients with Hematologic Malignancies and Hematopoietic Cell Transplantation. Clin Chest Med. 2017 Jun;38(2):317-331. doi: 10.1016/j.ccm.2016.12.008. Review.</citation>
    <PMID>28477642</PMID>
  </reference>
  <reference>
    <citation>Hohenthal U, Itälä M, Salonen J, Sipilä J, Rantakokko-Jalava K, Meurman O, Nikoskelainen J, Vainionpää R, Kotilainen P. Bronchoalveolar lavage in immunocompromised patients with haematological malignancy--value of new microbiological methods. Eur J Haematol. 2005 Mar;74(3):203-11.</citation>
    <PMID>15693789</PMID>
  </reference>
  <reference>
    <citation>Blauwkamp TA, Thair S, Rosen MJ, Blair L, Lindner MS, Vilfan ID, Kawli T, Christians FC, Venkatasubrahmanyam S, Wall GD, Cheung A, Rogers ZN, Meshulam-Simon G, Huijse L, Balakrishnan S, Quinn JV, Hollemon D, Hong DK, Vaughn ML, Kertesz M, Bercovici S, Wilber JC, Yang S. Analytical and clinical validation of a microbial cell-free DNA sequencing test for infectious disease. Nat Microbiol. 2019 Apr;4(4):663-674. doi: 10.1038/s41564-018-0349-6. Epub 2019 Feb 11.</citation>
    <PMID>30742071</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 5, 2019</study_first_submitted>
  <study_first_submitted_qc>August 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2019</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pneumonia</keyword>
  <keyword>NGS</keyword>
  <keyword>cell free DNA</keyword>
  <keyword>microbial cell free DNA</keyword>
  <keyword>immunocompromised</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Bacterial</mesh_term>
    <mesh_term>Pneumonia, Viral</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

